CVS Health Corp. reported quarterly results on Wednesday that beat analysts’ estimates on higher demand for COVID-19 tests and vaccinations due to the Omicron variant, while the drugstore operator also reaffirmed its annual earnings forecast. The company administered over 8 million COVID-19 tests and more than 20 million COVID-19 vaccines across the United States during the quarter. Despite robust demand for vaccines and tests, CVS maintained its earlier forecast for adjusted earnings between $8.10 and $8.30 per share in 2022. The midpoint of the outlook range was lower than analysts’ estimates of $8.28 per share, according to Refinitiv IBES data. The company in December warned of a significant decline in COVID-19 vaccinations and tests this year. On an adjusted basis, CVS earned $1.98 per share, compared with estimates of $1.93. Net income attributable to the company’s shareholders rose 34 percent to $1.31 billion, or 98 cents per share, in the …